Viromed Medical AG Secures Exclusive Agreement with CORIUS Group for Plasma Care® Deployment

On April 22, 2024, Viromed Medical AG announced a pivotal partnership with CORIUS Group, providing exclusive access to its Plasma Care® cold plasma therapy for 1,250,000 patients across CORIUS's vast network in Germany, Switzerland, and the Netherlands. This initiative positions Plasma Care® by Viromed as a leading innovative treatment in Europe’s dermatology and phlebology practices.

The collaboration is set to offer Plasma Care® an extensive reach, covering approximately 40% of Germany’s acute and chronic wound patients. With CORIUS Group operating 77 locations, including practices and clinics primarily in Germany, Viromed Medical AG expects the alliance to substantially boost their market presence and anticipates an earnings increase between EUR 0.28 and EUR 0.34 per share from 2025.

Uwe Perbandt, CEO of Viromed Medical AG, emphasized the strategic significance of this agreement, predicting a broader adoption of Plasma Care® by Viromed due to the influence and example set by the CORIUS Group across the region. This collaboration not only underscores the mutual confidence between the two entities but also enhances the profile of Viromed’s pioneering technology in modern wound care treatment.